Franklin Biolabs CEO Selected as a 2026 Women of Influence by the Philadelphia Business Journal
Learn more

Validated qPCR Assays for Biodistribution Assessment in Support of UK Clinical Trial Applications (CTAs)

PROVEN INTELLIGENCE ACCELERATING NEXT-GENERATION THERAPIES

Validated qPCR Assays for Biodistribution Assessment in Support of UK Clinical Trial Applications (CTAs)

CELL & GENE | RNA | BIOLOGICS

Quantitative Biodistribution: De-risking UK Clinical Trial Applications.

For gene therapy developers targeting UK Clinical Trial Applications (CTAs), quantitative polymerase chain reaction (qPCR) assays are the regulatory expectation for assessing vector biodistribution. A fully validated, GxP-compliant qPCR method provides precise quantification of vector DNA copies in both target and non-target tissues. This data is a key component of the nonclinical safety package, directly informing risk assessment by demonstrating the extent and persistence of vector presence post-administration.

    What is a typical LLOQ for a qPCR biodistribution assay?

    A: The Lower Limit of Quantification (LLOQ) is established on a per-assay and matrix basis during validation. We consistently develop methods that achieve the high sensitivity required to meet regulatory expectations for biodistribution studies, ensuring robust quantification.

    How does Franklin Biolabs ensure assay specificity for the vector sequence?

    A: We design primers and probes to target unique sequences within the vector construct, such as the promoter or transgene cassette. Specificity is confirmed through in silico analysis (BLAST) and empirically tested against non-transduced genomic DNA from the relevant species to rule out cross-reactivity.

    What tissue collection and processing protocols are required for qPCR analysis?

    A: Tissues must be snap-frozen immediately upon collection and stored at ≤ -70°C to preserve nucleic acid integrity. We provide sponsors with detailed collection SOPs. Our >100,000 sq ft facility is equipped for high-throughput tissue homogenization and automated DNA extraction to ensure consistency.

    What data are expected by the MHRA for a biodistribution study in a CTA submission?

    A: The UK’s regulatory authority, the MHRA, expects a comprehensive report including the full assay validation summary, quantitative data on vector copies per cell (or per microgram of DNA) for all tissues analyzed, clearance kinetics over time, and an assessment of potential germline transmission risk.

A close-up of a scientist in a lab, wearing blue gloves and examining the results of a gel electrophoresis or Western blot.

Quantifying Vector Biodistribution for UK Regulatory Success

A well-characterized biodistribution profile is a prerequisite for gaining MHRA approval to proceed to first-in-human trials in the United Kingdom. The objective is to build a quantitative map of vector localization and persistence. This dataset directly supports the proposed clinical starting dose and monitoring strategy by defining the safety profile of the investigational therapeutic.

Our bioanalytical teams develop and validate custom qPCR assays for precisely measuring vector copy numbers across a comprehensive panel of tissues. We generate the robust data packages required to confidently advance development programs.

*

Strategic Insights from AAV Clinical Development

Early-phase clinical trials with AAV vectors inform the nonclinical data required for new applications. For instance, studies have demonstrated that sustained transgene expression can be achieved even when an immune response to the vector capsid develops (PMID: 19706466). This highlights the importance of correlating vector persistence in target tissues with durable protein expression.

Clinical data also shows a clear dose-dependency for transgene expression, while underscoring the need for vector optimization to achieve desired therapeutic levels (PMID: 21609134). These insights reinforce the regulatory expectation for nonclinical studies to provide precise, quantitative data on vector biodistribution. A validated qPCR assay is the mechanism to generate this data, enabling a clear understanding of the relationship between administered dose, tissue localization, and potential for expression. This is a key component of the typical 18-24 month IND-enabling timeline.

A close-up of a pipette dispensing liquid into a rack of test tubes, set against a cool-toned, sterile background.

A scientist in protective gear pipetting a sample into a vial within a sterile laboratory hood.

GxP-Compliant Assay Lifecycle Management

Our approach to qPCR assay development and validation is aligned with global regulatory health authority expectations.

  • Assay Development: We design primers and probes for maximum specificity and efficiency, selecting the appropriate reference genes for data normalization.

  • Method Validation: The assay undergoes a rigorous GxP validation process, establishing parameters for accuracy, precision, linearity, and sensitivity (LLOQ/LOD).

  • Sample Analysis: All study samples are analyzed in a GxP environment, with comprehensive quality control measures to ensure data integrity. Franklin Biolabs has maintained a 100% IND/CTA approval success rate for our sponsors since 2019, a track record we are proud to continue since the Franklin Biolabs brand launch in 2024.

Commitment to Animal Welfare

All in vivo studies are conducted in full compliance with AAALAC guidelines. Our study designs incorporate the 3Rs principles (Replacement, Reduction, and Refinement) to ensure the highest standards of ethical conduct and animal welfare.

Scientific Process Diagram

This content is for informational purposes. For guidance specific to your therapeutic program, please contact our team for a consultation.

Explore More Capabilities